Your browser doesn't support javascript.
loading
Extracorporeal membrane oxygenation versus invasive ventilation in patients with COVID-19 acute respiratory distress syndrome and pneumomediastinum: A cohort trial.
Attou, Rachid; Redant, Sebastien; Velissaris, Dimitrios; Kefer, Keitiane; Abou Lebdeh, Mazen; Waterplas, Eric; Pierrakos, Charalampos.
Affiliation
  • Attou R; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Redant S; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Velissaris D; Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
  • Kefer K; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Abou Lebdeh M; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Waterplas E; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Pierrakos C; Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Artif Organs ; 48(9): 1038-1048, 2024 Sep.
Article in En | MEDLINE | ID: mdl-38660764
ABSTRACT

BACKGROUND:

Patients with severe respiratory failure due to COVID-19 who are not under mechanical ventilation may develop severe hypoxemia when complicated with spontaneous pneumomediastinum (PM). These patients may be harmed by invasive ventilation. Alternatively, veno-venous (V-V) extracorporeal membrane oxygenation (ECMO) may be applied. We report on the efficacy of V-V ECMO and invasive ventilation as initial advanced respiratory support in patients with COVID-19 and acute respiratory failure due to spontaneous PM.

METHODS:

This was a retrospective cohort study performed between March 2020 and January 2022. Enrolled patients had COVID-19 and acute respiratory failure due to spontaneous PM and were not invasively ventilated. Patients were treated in the intensive care unit (ICU) with invasive ventilation (invasive ventilation group) or V-V ECMO support (V-V ECMO group) as the main therapeutic option. The primary outcomes were mortality and ICU discharge at 90 days after ICU admission.

RESULTS:

Twenty-two patients were included in this study (invasive ventilation group 13 [59%]; V-V ECMO group 9 [41%]). The V-V ECMO strategy was significantly associated with lower mortality (hazard ratio [HR] 0.33 [95% CI 0.12-0.97], p = 0.04). Five (38%) patients in the V-V ECMO group were intubated and eight (89%) patients in the invasive ventilation group required V-V ECMO support within 30 days from ICU admission. Three (33%) patients in the V-V ECMO group were discharged from ICU within 90 days compared to one (8%) patient in the invasive ventilation group (HR 4.71 [95% CI 0.48-45.3], p = 0.18).

CONCLUSIONS:

Preliminary data suggest that V-V ECMO without invasive ventilation may improve survival in COVID-19-related acute respiratory failure due to spontaneous PM. The study's retrospective design and limited sample size underscore the necessity for additional investigation and warrant caution.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiration, Artificial / Respiratory Distress Syndrome / Extracorporeal Membrane Oxygenation / COVID-19 / Mediastinal Emphysema Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Artif Organs Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiration, Artificial / Respiratory Distress Syndrome / Extracorporeal Membrane Oxygenation / COVID-19 / Mediastinal Emphysema Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Artif Organs Year: 2024 Document type: Article Affiliation country: Country of publication: